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1
To investigate the attack rate and risk factors for prob-
able dengue fever, a cross-sectional study was conducted
of an Italian military unit after its deployment to East Timor.
Probable dengue was contracted by 16 (6.6%) of  241
army troops and caused half of all medical evacuations
(12/24); no cases were detected among navy and air force
personnel. 
D
engue fever (DF), caused by dengue virus (DENV)
serotypes 1 to 4, is an emerging public health problem
in many tropical countries (1). Dengue hemorrhagic fever
(DHF) and dengue shock syndrome (DSS), the severe
manifestations of DENV infection, were first recognized
in the 1950s in Southeast Asia and are today a leading
cause of childhood illness and death in many tropical
countries. More recently, DHF and DSS have emerged in
Central and South America and in the Pacific region (2,3).
DF is also recognized as an emerging health problem for
international travelers (4,5) and for troops deployed to
tropical countries (6,7).
In 1999, following a United Nations Security Council
recommendation, the International Force for East Timor
(INTERFET) was formed to restore peace on the island. In
November 1999, INTERFET troops totaled 11,000 from
17 countries. The Italian Armed Forces contributed 640
soldiers. 
DF is endemic in East Timor. The peak transmission
periods for DF are July–August and December–January,
corresponding to the rainy months (8). In 1998, at least
11% of hospital inpatient deaths in East Timor were attrib-
uted to DHF (9). In October 1999, a localized outbreak of
DF in a western district was attributed to serotype 3 (9) and
serotype 2 was isolated in December 1999 (10). Serotypes
2 and 3 were also responsible for DF cases among
Australian troops returning from East Timor in January–
February 2000 (11).
During deployment, a high attack rate of febrile illness
consistent with DF was reported among Italian troops. A
seroepidemiologic survey was therefore conducted in
February 2000 among soldiers returning home, in an
attempt to determine the cause of this outbreak and to
define infection rates and risk factors for infection.
The Study 
All Italian troops eligible for deployment are routinely
vaccinated against diphtheria/tetanus, tetravalent meningo-
coccal meningitis, measles/mumps/rubella, hepatitis A and
B, polio (with inactivated virus), typhoid fever (orally), and
yellow fever (YF). In this situation, troops were also vacci-
nated against Japanese encephalitis (JE) (Nakajama strain, 3
doses on days 0, 7, and 14) just before landing in East Timor. 
DF prevention consisted of the use of personal protec-
tion measures against mosquitoes (repellents applied to the
skin; permethrin-treated bed nets and uniforms) along with
environmental mosquito control. Adulticide spraying was
conducted weekly by pesticide-dispersal units but only
within the campsite and in its nearest surroundings, which
were also inspected daily to reduce or eliminate breeding
sites of vectors.
Italian troops were deployed in East Timor from late
September 1999 to mid-February 2000, and all 640 partic-
ipating military personnel were eligible for inclusion in the
study. Army soldiers were permanently based on the
ground and operated in Dili and surrounding areas, while
air force and navy personnel had only logistical tasks and
their presence in Dili was episodic, since they were main-
ly aboard ship or based in Darwin (Australia). 
A seroepidemiologic survey was conducted February
15–28, 2000, among troops returning to Italy after their 3-
month period of duty in East Timor. After informed con-
sent was obtained, peripheral blood specimens were drawn
and a written questionnaire administered. The question-
naire asked for personal health data, including all symp-
toms experienced during deployment and information
about compliance with personal protection measures.
Immunization status and clinical data concerning febrile
illness cases consistent with DF were obtained from stan-
dardized records kept by medical personnel. Soldiers and
navy/air force personnel were studied according to their
serologic status and disease status during deployment. 
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virus serotype 2 (DEN-2), yellow fever virus (YVF), and
West Nile virus (WNV) by hemagglutination-inhibition
test (HI). All serum specimens positive for DEN-2 were
tested by neutralization test (NT) for DEN-2. Additionally,
serum samples from participants who had experienced an
acute clinical syndrome suggestive of DF were directly
tested by NT for antibodies to DEN-2. Serum specimens
negative for DEN-2 were then tested for neutralizing anti-
bodies to dengue virus serotypes 1, 3, and 4 (DEN-1,
DEN-3 and DEN-4). 
The HI test was performed by the method of Clarke and
Casals (12) and NT as 90% plaque reduction neutralization
test (PRNT) on Vero cells. Briefly, serum specimens
(twofold dilutions) and virus (102 PFU) were incubated
overnight at 4°C, injected onto monolayers of Vero cells,
and overlaid with 1% Tragacanth gum (Sigma-Aldrich
S.r.I., Milan, Italy). Seven days postinfection, cells were
washed with saline and stained with 1% crystal violet in
20% ethanol (DEN-2 and DEN-3) or by immunodetection
assay (DEN-1 and DEN-4) as described (13). Vero cells
were propagated in minimum essential medium with
Earle’s salts (EMEM), supplemented with nonessential
amino acids, 10% fetal calf serum, 100 IE/mLof penicillin
G, and 100 IE/mL of streptomycin. 
The following viruses were used in the study: DEN-1
(Hawaii), DEN-2 (NGB), DEN-3 (H87), DEN-4 (H241),
YF (Asibi), and WN (Bratislava). Viruses were injected
into suckling mice by the intracerebral route. For NT, viral
stocks were prepared as 10% brain suspension in Hank’s
saline+7.5% bovine serum albumin (Sigma-Aldrich). For
HI, test antigens were prepared by sucrose-acetone extrac-
tion from mouse infected brains (12). Monoclonal antibod-
ies specific for DEN-1 or broadly reactive with flavivirus-
es were purchased from ATCC (ATCC HB112, ATCC
HB47) and used as mouse ascitic fluid after injection into
adult BALB/c mice.
Undetermined febrile illness was defined as an acute
clinical syndrome with temperature >38.5°C, unrelated to
diarrhea, malaria, or other identified infections. Suspected
dengue (14) was defined as an undetermined febrile illness
of 2–7 days’ duration, associated with two or more of the
following manifestations: headache, retroorbital pain,
myalgia, arthralgia, cutaneous rash. Antibody levels
>1:1,280 dilutions by HI (1,15) for DEN-2 and >1:20 dilu-
tions by NT to at least one of the four DENV serotypes
were considered supportive serologic evidence of a recent
dengue infection. Probable dengue (1,14) was defined as a
case compatible with the clinical description of suspected
DF and serologic findings supportive of a recent dengue
infection. 
The prevalence of undetermined febrile illness, sus-
pected dengue, and probable dengue was compared by chi-
square test among army and navy/air force personnel.
Since navy and air force personnel had a limited exposure
to the environment of East Timor, risk factors for probable
dengue were studied only in the army contingent. A uni-
variate analysis was first performed by Fisher exact test;
each risk variable was crossed with the prevalence of prob-
able dengue. Significance was tested at a level of α=0.05. 
A multiple logistic regression model was used to deter-
mine the relationship between the outcome of probable
dengue and a set of explanatory variables, and test the sig-
nificance of each variable while simultaneously account-
ing for demographic and risk factors. The following vari-
ables were included in the model: age, rank, previous
deployments in dengue-endemic areas, YF/JE vaccination,
night guards, skin repellents/permethrin-treated uni-
forms/bed nets use, and operational versus logistic tasks.
To identify a subset of variables significantly related to
probable DF, the stepwise procedure was performed with
the likelihood ratio test, by using at each step the p value
of 0.05 as entry criterion and the p value of 0.10 as
removal criterion. Univariate statistical analysis was per-
formed with EpiInfo 6.04d software (Centers for Diseases
Control and Prevention, Atlanta, GA, January, 2001) and
multivariate analysis by SPSS 11.0 software (SPSS Inc.,
Chicago, IL).
Conclusions
Of 640 eligible participants (280 army, 93 air force, and
267 navy), 595 (93%) were included in the study: 241
army, 88 air force, and 266 navy personnel (Table 1).
Serum specimens and questionnaires were obtained within
2 weeks after the troops’ return, in late February 2000. 
Some (14.5%) of the troops had previously been
deployed to DF-endemic areas, primarily Somalia and
Mozambique in 1992–1994. According to their immuniza-
tion status versus YF and JE viruses, 100 (41.5%) of the
241 army soldiers had received vaccinations against YFV
and JEV, 119 (49.4%) had been vaccinated against JEV
only, 2 (0.8%) against YF only, and 20 (8.3%) had not been
vaccinated.
Undetermined febrile illness was more frequently
reported (p<0.01) among army soldiers than among navy
and air force personnel: 85 (35.3%) of 241 versus 13
(3.7%) of 354 , respectively. All participants with suspect-
ed dengue (n=30), with serologic results supportive of a
recent dengue infection (n=27), and with a probable case
of dengue n=16), belonged to the army group (Table 2). 
The 16 participants with probable dengue showed also
a significant increase (p<0.01) in HI antibody titers to YFV
(>1:1,280 in 15/16 infected soldiers vs. 14/225 uninfected
soldiers) and WNV (>1:1,280 in 10/16 vs. 6/225). The
average interval between the onset of clinical manifesta-
tions suggestive of DF and the date when blood samples
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probable DF had a fever >38.5°C; a saddle-back fever pat-
tern was recorded for 5 (31.3%). Other reported symptoms
included myalgia and rash in 13 (81.3%); headache in 11
(68.8%); retroorbital pain in 9 (56.3%), and adenopathy in
3 (18.8%). No patients had DHF/DSS. 
The mean duration of probable DF cases was 7±3 days.
Moreover, 12 of the 16 patients with probable DF were
evacuated because of their clinical status. Univariate
analysis of risk factors for probable DF suggested a possi-
ble protective effect of JEV vaccination and personal pro-
tection measures (Table 3). However, logistic regression
analysis identified only a subset of variables significantly
related to probable dengue, whose risk was higher among
soldiers on duty in operational rather than logistic units,
and lower among participants with regular use of bed nets
(Table 4). 
Since most of soldiers had been previously vaccinated
with a flavivirus vaccine (YFV, JEV, or both), their
immune response to an eventual dengue infection was
expected to be a secondary (anamnestic) response, with
high-titer antibodies cross-reacting with several DENV
serotypes, as well as other flaviviruses (15). Thus, in spite
of the lack of paired serum specimens, high antibody titers
to DEN-2 by HI (>1:1,280) (1,16) and to any of the four
dengue virus serotypes by NT (>1:20), after an average of
36 days from the onset of clinical manifestations compati-
ble with dengue infection, may be considered supportive
serology of a recent flavivirus infection, likely acquired
during deployment. 
Overall, 6.6% of army soldiers contracted probable
dengue. No cases of probable DF were detected in the low-
exposure group of navy and air force personnel. The high
attack rate of probable dengue among the army contingent
may be due to several reasons. First, DF and DHF/DSS are
epidemic throughout Southeast Asia (3), including
Indonesia (17); in particular, the incidence of DF marked-
ly increased in East Timor in 1998–1999 (18). Secondly,
the multinational deployment to East Timor took place
during the rainy season (December–January), when the
risk of infection is high. 
Approximately 60% of troops with supportive serolog-
ic evidence of a recent dengue infection showed the clini-
cal manifestations of classic DF, 20% had milder symp-
toms, and 20% were asymptomatic. This finding agrees
with the U.S. troops’experience in Somalia in 1993, where
>85% of all DENV infections were symptomatic (6). In
contrast, the overall ratio of inapparent to clinical DENV
infections is quite high in persons living in disease-endem-
ic areas, as in Indonesia, where it has been reported to be
as high as 9.3 (17). 
Performing duties outside the camp was associated
with a significantly higher risk of infection, probably
because vector control activities were regularly carried out
within the compound. Regular use of bed nets was the only
personal protection measure that significantly decreased
the risk of contracting probable dengue. This finding is not
new (6) and may have been because some of the troops
were frequently on duty at night and thus slept during the
day when the biting activity of dengue vectors is highest.
Otherwise, the regular use of repellents (applied to the
skin) and permethrin-treated uniforms seemed to decrease
the risk for dengue infection, but the differences between
those who did not follow these practices and those who did
were not significant statistically. 
DF is therefore an emerging problem for troops
deployed to dengue-endemic areas, mainly because of the
lack of effective preventive measures, the high attack rate,
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Table 1. Characteristics of Italian military personnel, East Timor, 1999–2000 
Feature  Army  Navy  Air Force  Total 
No. participants  241  266  88  595 
Mean age (years ± sd)  27 ± 7  28 ± 7  35 ± 7  – 
Time of deployment  22/Sep/99–16/Feb/00  21/Oct/99–19/Feb/00  19/Sep/99–17/Feb/00  – 
Mean duration of deployment (days ± sd)  100 ± 25  109 ± 14  41 ± 23  – 
Person months   803  968  102  1,873 
Presence in East Timor for >90 days (no. soldiers)  241  0  0  241 
Episodical presence in East Timor (no. soldiers)  0  266  88  354 
Table 2. Clinical and serologic findings of recent dengue infection among Italian troops 
Serologic findings of recent dengue infection
a 
Clinical assessment  No. supportive (%)  No. not supportive (%)  Total no. (%) 
Undetermined febrile illness
a  6 (22.2)  49 (22.9)  55 (22.8) 
Suspected dengue
b  16 (59.3)  14 (6.5)  30 (12.4) 
Asymptomatic  5 (18.5)  151 (70.6)  156 (64.7) 
Total  27 (100)  214 (100)  241 (100) 
aAll military personnel with supportive serologic findings belonged to the army contingent (N=241). Probable dengue cases are represented by the 16 soldiers with 
clinical manifestations compatible with DF (suspected dengue) and serologic findings supportive of a recent dengue infection. 
bCases are defined in the section “Materials and Methods.” the high symptomatic/inapparent infection ratio, and the
long period of being unfit for duty after the acute phase of
the disease. DF may thus seriously disrupt the readiness of
a military unit. Moreover, previously infected soldiers
redeployed to disease-endemic areas may be at increased
risk for DHF/DSS complications. Persons previously
infected by a DENV serotype may be at higher risk of
developing DHF/DSS, if they are subsequently infected by
a different serotype. Such risks should be taken into
account while planning international peace-keeping opera-
tions, and the risk of DHF among previously dengue-
infected military personnel should be evaluated.
Cross-reaction by antiflavivirus antibodies induced by
JEV vaccine may otherwise afford some cross-protection
against DF. JEV vaccine (Nakajama strain) seems to
decrease the attack rate of DHF and reduce the severity of
cases for a short time (19). More recently, researchers have
noted that prior vaccination of hamsters with a live, atten-
uated JEV vaccine strain (not licensed for human use) and
a St. Louis encephalitis virus wild strain seems to reduce
the severity of a subsequent WNV infection (20). Our data
suggest that prior vaccination with the commercially avail-
able JEV inactivated vaccine for human use (Nakajama
strain) may have some protective effect against subsequent
probable DF. The decrease was, however, not significant,
according to the multiple logistic regression model we
used. 
Our data suggest that effectiveness of routine protective
measures against vector mosquitoes is far from satisfacto-
ry. A tetravalent dengue vaccine is needed to effectively
reduce the risk for DF and DHF/DSS among troops
deployed to tropical areas as well as to protect long-term
international travelers to dengue-endemic countries.
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